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Abstract: Most lymphomas that involve the ocular adnexal structure are low grade, B cell, 
non-Hodgkin’s lymphomas. The treatment depends upon the grade and stage of the disease. High 
grade lymhoma requires treatment with systemic chemotherapy whereas the localized low grade 
(extranodal marginal zone lymphoma) can be successfully managed with local radiotherapy. 
Chlamydia psittaci infection is associated with low grade ocular lymphoma; however there is 
wide geographic variation in the strength of this association. Blanket antibiotic therapy is not 
advised unless there is proof of an infective agent. The monoclonal antibody, rituximab, may 
be successful for CD20 positive lymphoma, although it is likely that rituximab will have better 
long-term results when used in combination with systemic chemotherapy.
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Treatment options for ocular adnexal  
lymphoma (OAL)
OAL comprises lymphoma that affects the orbit, lid, lacrimal gland and conjunctiva. The 
treatment of lymphoma depends on the type, location and stage of the disease. The majority 
(50%–90%) of OAL is low-grade mucosa associated lymphoid tissue (MALT) lymphoma. 
According to the World Health Organization modification of the REAL classification, 
MALT lymphoma is classified as extranodal marginal zone lymphoma (EMZL). The other 
4 main types of OAL are follicular cell, mantle cell, diffuse large B cell (DLBCL) and 
lymphoplasmacytic lymphoma. They are all B cell, non-Hodgkin’s lymphoma, the subtype 
derived from various stages of B cell maturation. The new classification of lymphoma is 
dependent on histological, immunophenotypic and molecular genetic analysis. Hodgkin’s 
lymphoma does not affect the ocular adnexal structures unless there is widespread systemic 
involvement or a history of previous systemic Hodgkin’s lymphoma.
According to the Ann-Arbor staging system lymphoma confined to the orbit is 
designated as stage I, involvement of adjacent structures (sinuses, tonsil and nose) is 
stage II. Stage III is abdominal nodal disease below the diaphragm and IV by definition 
refers to disseminated involvement of one or more extra-nodal sites (eg, liver, bone) 
and “E” is used when there is a local extra-nodal extent (eg, IE, IIE, IIIE and IVE). 
Approximately 20% of the patients will have stage III or IV disseminated involvement. 
The grading system is similar to nodal lymphomas.
Broadly speaking, OAL with systemic involvement requires systemic treatments 
whereas low-grade (EMZL or follicular cell) lymphoma localized to the eye can be Clinical Ophthalmology 2009:3 690
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very successfully managed with local treatments such as 
cryotherapy, surgical excision or external beam radiotherapy. 
When considering local treatment it is important to exclude 
bilateral ocular involvement. Even in the absence of clinical 
signs an MRI of both orbits may reveal a contralateral retro-
orbital mass lesion. Recurrence in contralateral orbit is seen 
in 10% of patient with orbital lymphoma.
Staging investigations should include full blood count, 
hepatic enzymes including LDH, CT abdomen, chest and 
pelvis, MRI or CT of the orbits, and a bone marrow biopsy 
and aspirate.
Observation
This is only appropriate for low-grade lymphoma localized 
to the conjunctiva or orbit with no systemic involvement. 
A biopsy is required to grade the lymphoma.
Surgery and cryotherapy
Surgical excision or cryotherapy is most appropriate for 
localized stage 1 conjunctival EMZL/MALT lymphoma.1 
This is not curative treatment but can control local disease and 
relieve local symptoms. Tanimoto et al2 reported very good 
local control of stage 1 MALT lymphoma following biopsy or 
surgical resection alone. Patients were followed for a median 
of 7.1 years, 69% of patients did not require any further 
treatment. The estimated overall survival rates were 94% at 
10 years and 71% at 15 years.2 Although, patients should be 
closely followed for recurrence, histological transformation 
of the tumor and long-term systemic manifestations of 
lymphoma.
Radiotherapy
This has been the mainstay of treatment for localized OAL 
for many years with excellent control rates. Central nervous 
system prophylactic radiotherapy is not required as metastatic 
intraocular or brain involvement is rare.3 The dose of radiation 
is tapered according to the grade of the lymphoma, 28 to 36 
Gy for low-grade lymphoma and 30 to 40 Gy for high-grade. 
EMZL, lymphoplasmacytic and follicular cell lymphoma 
are considered low grade, whereas DLBCL and mantle cell 
are high-grade lymphomas. Five-year local control rates for 
EMZL and follicular lymphoma after a dose of more than 
30 Gy reach 100%.4 However, high rates of delayed systemic 
recurrence suggest long-term follow up studies are required 
to assess the true benefit of radiotherapy.5
There is ongoing debate about use of lens shielding 
radiotherapy to protect the lens from cataract formation. 
Some studies show no effect on local recurrence, whereas 
in others all recurrences have occurred in patients whose 
lenses were shielded.6,7 Partial orbit volume irradiation leads 
to unacceptable incidence of intraorbital recurrence and is 
presently not recommended. Ocular complications, including 
dry eye and cataract are frequently reported in patients that 
have long-term follow up.8 These localized complications 
need to be kept in mind by the treating oncologist.
Immunotherapy: interferon  
(IFN-alpha)
IFN-alpha has been used for the treatment of systemic 
lymphoma for more than 20 years. There are few reports of 
its local use for ocular lymphoma. One study treated 5 patients 
with intralesional IFN-alpha using an intensive protocol.9 
An initial complete response was seen in all patients with stage 
I OAL, one patient with more advanced disease at presentation 
(stage IIA) died from systemic lymphoma. Long-term follow 
up studies are required to assess the value of this treatment.
Immunotherapy: monoclonal 
antibody
Rituximab is a monoclonal antibiotic against CD20 positive 
B cells, which is being considered as an alternative first line 
treatment for localized CD20 positive OAL to avoid the ocular 
complications of radiotherapy. Antibody-induced destruction 
of CD20 positive B cells can occur by apoptosis, complement 
mediated cytolysis and antibody-dependent, cell-mediated 
cytoxicity. It may be used instead of systemic steroids for benign 
lymphoid hyperplasia. Rituximab has also been used as mono-
therapy for localized EMZL/MALT, in some cases complete 
regression can be achieved. Initial responses are encouraging 
but the efficacy of rituximab is lower than that reported for 
gastric MALT lymphoma,10 as long-term distal relapse is 
seen in 50% of cases. Very few case series are published on 
the effect of single agent rituximab on ocular MALT/EMZL. 
Ferreri and associates achieved regression of MALT lymphoma 
using first line single agent rituximab in all 5 newly diagnosed 
patients; however early relapse was seen in 4 of the 5 patients.10 
Therefore, close follow up intervals are required to detect early 
relapse when rituximab is used alone. Rituximab was not 
successful for the treatment of local relapse.10
Greater success is achieved when rituximab is used in 
combination with chemotherapy. Rituximab and chlorambucil 
were used as first-line therapy for 9 patients with newly 
diagnosed EMZL. Treatment achieved complete remission 
in 89% with a median follow up of 2 years.11
First-line chemotherapy is often treatment of choice 
for mantle cell OAL, as a high proportion of patients have Clinical Ophthalmology 2009:3 691
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systemic involvement at presentation. Encouragingly, 
rituximab containing chemotherapy for mantle cell OAL 
had a significantly better 5-year survival than patients 
receiving chemotherapy alone (83% overall 5-year survival 
verses 8%).12 Combination treatment with rituximab and 
chemotherapy or radioimmunotherapy may achieve a more 
durable local response and improve patient survival.11–13
Chemotherapy
Chemotherapy is reserved for treatment of OAL when there 
is systemic involvement, except for the high-grade DLBCL 
when systemic chemotherapy is first-line treatment even for 
stage I disease. The standard regimen is cyclophosphamide, 
doxorubicin, vincristine and prednisolone (CHOP). 
Systemic steriod alone does not offer effective long-term 
control. More recently chlorambucil and the purine analogs 
fludarabine, clardarabine and pentostatin have also been 
used. The Extranodal Lymphoma Study Group (IELSG) is 
currently recruiting patients to a clinical trial investigating the 
role of rituximab alone or in combination with chlorambucil 
for MALT lymphoma (IELSG #19).14
Systemic antibiotics
Novel mechanisms of tumor pathogenesis have related 
lymphoma to infection leading to new approaches to 
diagnosis and treatment. Chronic antigen stimulation may 
result in an abnormal lymphoproliferative response that 
ultimately develops into lymphoma. This association is most 
profound for gastric MALT cell lymphoma, which is related 
to chronic gastritis from Helicobacter pylori infection in more 
than 90% of cases.15 H. pylori has been isolated from ocular 
lymphoma specimens. However, H. pylori eradication is not 
effective treatment for OA MALT lymphoma.16
Chlamydia psittaci infection has also been linked to 
OAL. Ferreri and associates17 identified C. psittaci in 80% of 
Italian OA MALT lymphoma specimens. In Korea, C. psittaci 
was isolated in 78% of OA MALT lymphoma specimens.18 
Subsequent reports from South Florida, New York State, 
Chicago, Netherlands, Japan and France failed to identify 
DNA for C. psittaci in any of their OA MALT lymphoma 
specimens.19–24 There is wide geographical variation in the 
prevalence of C. psittaci infection in OA MALT lymphoma 
specimens.25 Of the European countries studied, the lowest 
rate of infection (12%) was present in the UK.
Results following first line antibiotic treatment are 
variable.26 Abramson and coworkers27 documented a clinical 
response following antibiotic treatment in 3 patients with 
OA MALT lymphoma. Ferreri and associates28 recorded an 
objective response following oral doxycycline in 4 out of 
9 patients with C. psittaci positive OA MALT lymphoma. 
Although, Grunberger and associates29 were unable to 
replicate these results. In a multicenter prospective trial, 
27 patients with ocular adnexal MALT lymphoma were 
treated with oral doxycycline. C. psittaci DNA positive 
cases had an overall response rate of 64%, the response 
was of short duration.30 A clinical response was also seen in 
38% in C. psittaci DNA negative cases.30 Lack of response 
to antibiotic therapy may be a reflection of the biological 
and genetic heterogeneity of this disease. The Extranodal 
Lymphoma Study Group (IELSG) has activated a prospective 
trial (IELSG #27) into OAL to explore the role of antibiotic 
treatment and to identify potential infectious agents.14
In summary, advances in our knowledge of the immu-
nophenotypic and genetic alterations in lymphoma cell lines 
have led to a better understanding of the pathogenesis of the 
disease. The interplay between a possible infective agent and 
the immune response has allowed a new wave of treatment 
possibilities. Ongoing clinical trials will reveal the truth 
about new treatments. Staging the patient at diagnosis guides 
subsequent management and local treatments should be 
reserved for localized disease. However, the practical approach 
to the patient remains “first do no harm” and with this in mind 
ocular oncologists are tempted to administer an initial trial 
of oral antibiotics for stage 1 MALT lymphoma. Although, 
general blanket treatment with antibiotics should be discouraged 
unless there is proof of an infective agent. We recommend 
a diagnostic biopsy with immunophenotyping and genetic 
analysis to determine the grade of the lymphoma combined 
with PCR analysis to determine the presence of an infective 
agent. If H. pylori or C. psittaci infection is found a trial of 
oral doxycycline (100 mg twice daily for 3 weeks) is worthwhile. 
We have also seen some early impressive responses to systemic 
rituximab (weekly intravenous infusion over 6 weeks). However, 
close follow up is required as others have reported early local 
relapse with rituximab alone.10 At present, despite the ocular 
side effects, localized radiotherapy still remains the standard 
first-line treatment for stage I low-grade OAL.
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